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The CaaX proteases Rce1p and Ste24p can independently promote a proteolytic step required for the maturation of certain isoprenylated
proteins. Although functionally related, Rce1p and Ste24p are unrelated in primary sequence. They have distinct enzymatic properties, which
are reflected in part by their distinct inhibitor profiles. Moreover, Rce1p has an undefined catalytic mechanism, whereas Ste24p is an
established zinc-dependent metalloprotease. This study demonstrates that both enzymes are inhibited by peptidyl (acyloxy)methyl ketones
(AOMKs), making these compounds the first documented dual specificity inhibitors of the CaaX proteases. Further investigation of AOMK-
mediated inhibition reveals that varying the peptidyl moiety can significantly alter the inhibitory properties of AOMKs toward Rce1p and
Ste24p and that these enzymes display subtle differences in sensitivity to AOMKs. This observation suggests that this compound class could
potentially be engineered to be selective for either of the CaaX proteases. We also demonstrate that the reported sensitivity of Rce1p to TPCK
is substrate-dependent, which significantly alters the interpretation of certain reports having used TPCK sensitivity for mechanistic
classification of Rce1p. Finally, we show that an AOMK inhibits the isoprenylcysteine carboxyl methyltransferase Ste14p. In sum, our
observations raise important considerations regarding the specificity of agents targeting enzymes involved in the maturation of isoprenylated
proteins, some of which are being developed as anti-cancer therapeutic agents.
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Rce1p and Ste24p2 are proteases that mediate the maturation
of certain lipid-modified proteins, specifically those whose
precursors have a C-terminal tetrapeptide CaaX motif (C—Abbreviations: Z, benzyloxycarbonyl; AOMK, (acyloxy)methyl ketone; DMSO
trans-carboxyoxiran-2-carbonyl)-L-leucyl]agmatine; ICMT, isoprenylcysteine carbo
L-phenylalanyl-chloromethylketone; MMTS, methyl methanethiosulfonate; MSA, m
PHMS, p-hydroxymercuriphenylsulfonic acid; PMSF, phenylmethylsulfonylfluoride
⁎ Corresponding author. Tel.: +1 706 583 8241; fax: +1 706 542 1728.
E-mail address: wschmidt@bmb.uga.edu (W.K. Schmidt).
1 These authors contributed equally to this body of work.
2 There are various name designations for the Ras converting enzyme and the S
Zmpste24/FACE-1 (human), AtRce1/AtFACE-2 and AtSte24 (A. thaliana), CeRce1p
Type II (Rce1p) CaaX proteases. In order to clearly convey the ortholog being describ
standard naming convention for these enzymes—a species identifier followed by R
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.03.004cysteine; a—aliphatic; X—one of several amino acids) [1,2].
Their substrates (i.e., CaaX proteins) typically undergo three
ordered post-translational modifications: covalent attachment of
an isoprenoid lipid to the cysteine, proteolytic removal of the
aaX tripeptide, and carboxyl methyl esterification of the, dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic acid; E64, N-[N-(L-3-
xyl methyltransferase; TLCK, tosyl-L-lysyl-chloromethylketone; TPCK, tosyl-
ersalyl acid; NEM, N-ethylmaleimide; PHMB, p-hydroxymercuribenzoic acid;
.
terile 24 protein—Rce1p and Ste24p/Afc1p (S. cerevisiae), Rce1/FACE-2 and
/CeFACE-2 and CeSte24p/CeFACE-1 (C. elegans), and the Type I (Ste24p) and
ed, and with apologies to others who study these enzymes, we have opted to use a
ce1p or Ste24p.
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a common function and are both ER-localized integral
membrane proteins that possess multiple transmembrane
spans, they are otherwise unrelated by primary sequence [4].
Several substrates of Rce1p have been described. Many
but not all Rce1p substrates are involved in signal
transduction. Some have key roles in cellular transformation
(e.g. Ras, RhoB). Thus, agents that inhibit the maturation of
CaaX proteins are hypothesized to have chemotherapeutic
potential [3,5]. The testing of this hypothesis has led to the
development of farnesyltransferase inhibitors that are being
examined for their ability to moderate tumor growth [6–9].
The inhibition of Rce1p holds similar anti-cancer potential
[3,10,11]. By contrast, few substrates have been described
for Ste24p. One specific target is the lamin A precursor.
Defects in lamin A maturation are associated with abnormal
musculo-skeletal development, varied laminopathies, and
progeroid syndromes [12–14]. The only other known target
of Ste24p is the precursor of the yeast a-factor mating
pheromone, which is also a target of Rce1p [1,15]. For both
of its targets, Ste24p appears to catalyze not only CaaX
cleavage but also a second cleavage distal to the farnesylated
cysteine [16,17]. Other targets of Ste24p likely exist but have
not yet been identified. The yeast a-factor precursor is thus
far unique as a CaaX protein in being a substrate of both
Ste24p and Rce1p [1]. Once processed by either Rce1p or
Ste24p, CaaX proteins are obligatory substrates of the
isoprenylcysteine carboxyl methyltransferase (ICMT) [18].
The minimum recognition determinant for this ER-localized
membrane protein is a farnesyl cysteine [19,20]. Both
proteolysis and carboxyl methylation can significantly alter
the function, localization, and other properties of CaaX
proteins [1,10,21].
The modern classification system for proteases designates
four categories of proteolytic mechanisms: serine/threonine,
cysteine, aspartic, and metal-dependent. Ste24p is a zinc-
dependent metalloprotease. As expected, Ste24p possesses a
consensus zinc metalloprotease motif that is essential for its
activity, requires zinc for optimal activity, and is inhibited by
zinc chelating compounds such as 1,10-phenanthroline [16,22].
By contrast, the mechanistic classification of Rce1p has eluded
definition, primarily because it lacks a readily identifiable
protease motif. Rce1p has also been refractory to purification,
which has hindered detailed biochemical and structural analysis
of this integral membrane protein.
Rce1p is reportedly sensitive to certain serine/cysteine
protease inhibitors (e.g. TPCK), and this sensitivity has been
used in part to support a proposed cysteine protease
classification for Rce1p [23–26]. Nevertheless, TPCK-sensi-
tivity should be viewed cautiously when used as an indicator
of protease classification because TPCK covalently modifies
the active site histidine residues of both serine and cysteine
proteases (e.g. chymotrypsin and papain, respectively), and
possibly other catalytic types. Moreover, Rce1p is insensitive
to thiol-modifying agents such as NEM and iodoacetamide,
which further counters a cysteine protease classification for
this enzyme [24,27]. Certain mutational studies are alsoinconsistent with a cysteine protease classification for Rce1p
[28]. Supporting a proposed metalloprotease classification for
Rce1p are the observations that it requires certain glutamate
and histidine residues for activity and its inhibition by 1,10-
phenanthroline [24,28]. Nevertheless, the partial sensitivity of
Rce1p to a non-chelating form of phenanthroline (i.e., 4,7-
phenanthroline) suggests that the inhibition by this compound
class may be unrelated to chelating effects. It is also formally
possible that Rce1p utilizes a novel proteolytic mechanism.
The recent identification of a carboxyl peptidase requiring a
Glu–Gln catalytic dyad reveals that additional proteolytic
mechanisms may yet be discovered [29].
Several inhibitors of Rce1p in addition to those discussed
above have been described [23–27,30–35]. These fall into two
classes: general non-specific inhibitors and substrate mimetics.
The first class includes chloromethyl ketones, organomercurials
(e.g. MSA, PHMB, and PHMS), and certain metal ions (i.e.,
Cu2+ and Zn2+). Rce1p is reportedly insensitive to many broad-
spectrum inhibitors, such as EDTA, EGTA, antipain, chymos-
tatin, pepstatin A, leupeptin, E64, and is partially sensitive to
MMTS. It should be noted that the sensitivity of Rce1p to the
serine protease inhibitors PMSF and DFP and the alkylating
agent NEM has been inconsistently reported [24,27,30,31]. The
second class of Rce1p inhibitors is represented by substrates
with non-cleavable peptide bonds, isoprenoid-like compounds,
and bisubstrate analogues (i.e., compounds containing both a
farnesylmimetic and peptidomimetic). These compounds typi-
cally act competitively to inhibit Rce1p, and some have IC50
values in the nM range [27,32,34–36]. Despite the various
studies probing the enzymology and inhibitor profile of Rce1p,
the mechanistic classification of Rce1p remains undefined, with
cysteine and metalloprotease categories having been indepen-
dently proposed [24,37].
In this study, we have compared the inhibitor profiles of
Rce1p and Ste24p orthologs using two primary agents,
chloromethyl ketones and peptidyl (acyloxy)methyl ketones
(AOMKs). AOMKs were included in our analysis because a
pilot screen of about 20 compounds yielded an AOMK as a
candidate yeast Rce1p inhibitor. Compounds of this class
reportedly inhibit the cysteine protease cathepsin B [38–41], but
the impact of AOMKs on Rce1p activity had not previously
been reported. We evaluated three distinct orthologs of each
enzyme to assess whether enzymatic profiles are evolutionarily
conserved within each group and investigated the inhibitor
profiles of these enzymes using two distinct assays to
independently confirm our observations. The orthologs were
all expressed using the yeast system to aid comparative
evaluations. We present evidence that the inhibition of Rce1p
and Ste24p by chloromethyl ketones is substrate-specific, and
we report for the first time that AOMKs can inhibit both of the
CaaX proteases as well as the yeast ICMT Ste14p. Additionally,
we demonstrate that the peptidyl portion of AOMKs can
modulate the inhibitory properties of this class of agent. Besides
providing a new reagent that may be useful for probing the
enzymology of CaaX modifying enzymes, this study under-
scores the caution that must be taken when evaluating the
inhibitor profiles of these enzymes.
Fig. 1. Chemical structures of peptidyl (acyloxy)methyl ketones. The general
chemical structure of an AOMK is shown (top). The names of the compounds
used in this study are listed along with the substitutions specific to the indicated
compound.
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2.1. Yeast strains and plasmids
The yeast strains used in this study were SM3614 (MATa trp1 leu2 ura3 his4
can1 ste24Δ::LEU2 rce1Δ::TRP1) and RC757 (MATα sst2-1) [15,42]. Plasmid-
bearing versions of SM3614were generated by transformation with the indicated
plasmids according to published methods [43]. Transformed strains were
routinely grown at 30 °C on synthetic complete dropout (SC−) media, as
previously described [44]. The Rce1p, Ste24p, and Ste14p-encoding plasmids
used in this study have previously been described and are listed in Table 1.
2.2. Substrate reagents
The peptide substrates used in this study were made synthetically. The
fluorogenic substrates ABZ-KSKTKC(farnesyl)QLIM, ABZ-KSKTKC(farne-
syl)VQLM, and ABZ-KSKTKC(farnesyl)VIQL were initially obtained from
Wyeth Research (Pearl River, NY) and subsequently purchased from AnaSpec
(San Jose, CA). ABZ is aminobenzoic acid, and QL is lysine ε-dinitrophenyl.
The a-factor-based substrate YIIKGVFWDPAC(farnesyl)VIA was purchased
from California Peptide (Napa, CA).
2.3. Peptidyl (acyloxy)methyl ketones and other compounds
Several distinct AOMKs were evaluated in this study (Fig. 1). Z-Phe-Lys-
2,4,6-trimethylbenzoyloxymethyl ketone (FKBK(CH3)3) was purchased from
Bachem (Torrance, CA). A Phe-Ala derivative (FABK(CH3)3) was a gift fromDr.
Jan Potempa (Jagiellonian University, Poland), and was subsequently synthe-
sized in house according to standard chemical methods that will be described
elsewhere (Porter, Dechert, Breevoort, Hembree, Dore and Schmidt, in
preparation). Phe–Arg (FRBK(CH3)2), Phe–Gly (FGBK(CH3)2), AcTyr–Phe–
Arg (YFRBK(CH3)2), and AcTyr–Phe–Gly (YFGBK(CH3)2) derivatives were
obtained from Dr. Matthew Bogyo (Stanford University). Additional amounts of
FRBK(CH3)2 and FGBK(CH3)2 were synthesized in house according to standard
chemical methods that will be described elsewhere (Porter, Dechert, Breevoort,
Hembree, Dore and Schmidt, in preparation). All inhibitors were dissolved in
DMSO, with the exception of TLCK, which was dissolved in H2O. Other
chemical reagents were purchased from Sigma-Aldrich.
2.4. In vitro fluorescence-based CaaX proteolysis assay
An established fluorescence-based assay was used to monitor Rce1p-
dependent cleavage of a quenched fluorogenic peptide substrate [36]. By using
a slightly different substrate, this assay was adapted to monitor Ste24p activity. In
brief, the assay involves mixing an appropriate fluorogenic substrate with
membranes derived from yeast over-expressing the appropriate CaaX protease.
Themembranes used as the source of activity were isolated as 1mg/ml total protein
stocks in Lysis Buffer (50 mM Tris, pH 7.5, 0.2 M sorbitol, 1 mM EDTA, 0.2%
NaN3, protease inhibitors chymostatin, leupeptin, pepstatin, aprotinin, PMSF)
according to our reported methods [22,28]. Prior to use, the membranes were
diluted to 0.5 mg/ml with Assay Buffer (100 mM HEPES, pH 7.5, 5 mMMgCl2)
and preincubated with DMSO or inhibitors for 10 min at 30 °C, unless otherwise
indicated. The substrate was typically diluted with Assay Buffer to 40 μM from aTable 1
Plasmids used in this study
Plasmid Genotype Reference
pRS426 2μ URA3 [49]
pSM1282 2μ URA3 PPGK-His::HA::STE24 [16]
pSM1317 2μ URA3 STE14 [20]
pWS182 2μ URA3 HA::HsZmpSte24 [28]
pWS335 2μ URA3 PPGK-His::HA::HsRce1Δ22 [28]
pWS402 2μ URA3 PPGK-AtRCE1::HA [26]
pWS450 2μ URA3 AtSTE24::HA [26]
pWS479 2μ URA3 PPGK-RCE1::HA [28]1 mM stock; a range of concentration (0–200 μM) was used in instances where
kinetic parameters were sought. Assays were initiated by mixing equal volumes
(50μl) of themembrane and substrate dilutions in a 96-well plate suitable for use in
a microtiter plate fluorometer. The fluorescence in the samples was measured at
420 nm every 30 s over a 35- to 60-min time course at 30 °C using either a
SpectraMax Gemini EM fluorometer (Molecular Devices) or a Bio-Tek Synergy
fluorometer equipped with a 320/420 nm excitation/emission filter set. The
collected data were graphed and initial linear slopes determined using Microsoft
Excel. These values were used to calculate % activities relative to the DMSO-
treated enzyme, which was always included as a control in each reaction set.
2.5. Kinetic analyses
Kinetic parameters were typically determined using nonlinear regression
methods (Prism 4.0 GraphPad Software Inc.). The Kitz–Wilson approach was
used to compare the time-dependent interactions of TPCK and FKBK(CH3)3
with Rce1p [45]. According to the associated theory, an irreversible active-site
directed inhibitor of an enzyme should show a linear decrease in ln[Et/E0] with
time of incubation, where Et is the activity at time t and E0 is the activity of the
uninhibited enzyme at time zero; the slope of this line is defined as the apparent
inactivation rate Kapp. TPCK was previously shown to be an irreversible active-
site inhibitor of bovine Rce1p by this analysis [23].
2.6. In vitro a-factor-based CaaX proteolysis assay
An established assay was used for the in vitro production of bioactive a-factor
from the farnesylated pentadecapeptide precursor YIIKGVFWDPAC(farnesyl)
VIA [16]. In brief, the assay involves mixing membranes derived from yeast over-
expressing the appropriate CaaX protease with the farnesylated substrate. The
membranes were isolated and diluted for the assay as described above. The
substrate was diluted from a 100 μM stock to 40 μM using Assay Buffer (see
Fig. 2. Rce1p orthologs have sensitivity to FKBK(CH3)3 and TPCK as measured
using a fluorescence assay. The inhibitory effect of various compounds on the
activity of S. cerevisiae (Sc), A. thaliana (At), and human (Hs) Rce1p (A–C,
respectively) was evaluated using a fluorescence-based assay. The assay
monitors cleavage of a quenched fluorogenic farnesylated peptide that is based
on the C-terminal sequence of the K-Ras4b precursor (ABZ-KSKTKC(farnesyl)
QLIM). The indicated Rce1p enzyme was over-expressed using a plasmid-based
system in yeast lacking the chromosomal copies of RCE1 and STE24.
Membranes enriched for Rce1p were isolated and used as the source of
enzymatic activity. The compounds evaluated were FKBK(CH3)3 (FKBK),
FABK(CH3)3 (FABK), TPCK, TLCK, and DMSO as a control. All compounds
were used at 250 μM to pretreat the yeast-derived membranes used as the source
of enzymatic activity. The DMSO-treated sample was defined as having 100%
activity for each membrane set to facilitate cross-species comparative analyses.
Each value represents the average activity of three independent reactions with
the positive standard deviation of the measurements shown.
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substrate and membrane components in a 96-well plate suitable for use in a PCR
thermocycler. After an 8-min incubation at 30 °C, the samples were heated to 95 °C
for 1 min to inactivate enzymatic activity, cooled, and supplemented with S-
adenosylmethionine (1.7 mM final) and yeast membranes containing the Ste14p
ICMT (0.33 mg/ml final) to initiate carboxyl methylation of cleaved products. For
reactions with limited S-adenosylmethionine and Ste14p, the concentrations were
160 μM and 0.1 mg/ml respectively. The Ste14p-membranes were derived from a
CaaX protease-deficient strain as previously described [16]. After 60 min of
incubation at 30 °C, the samples were supplemented with copper sulfate (1.2 mM
final) to stop the methylation reaction. The a-factor activity in each sample was
determined using a biological response assay in which yeast supersensitive to the
a-factormating pheromone (RC757) undergo growth arrest in the presence of 7 nM
or greater concentrations of pheromone [46]. The activity observed for a two-fold
dilution series of a sample was compared to that of other samples for an assessment
of relative activity measurements.
2.7. Inhibitor and chaotropic agent treatments
To assess the inhibition by the compounds described in this study, the above
assay protocols were modified such that diluted membrane samples were
pretreated with the appropriate compound or control (DMSO or H2O) for 10 min
at 30 °C prior to use. The pre-treated sample was split into two portions for use
in each assay when evaluating substrate-specific effects. For reversibility
experiments, pre-treated membranes were recovered by centrifugation at
16,000×g for 15 min, washed twice with 2-fold excess of Wash Buffer (a 1:1
ratio of Lysis Buffer and Assay Buffer) containing varying amounts of NaCl (0–
1.5 M) or urea (0–0.125 M), and finally resuspended to the original input
volume with Wash Buffer lacking added salt or urea. The resuspended
membranes were used directly in the fluorescence-based assay along with an
unprocessed control to confirm that inefficient membrane recovery was not the
reason for observed decreases in activity.
3. Results
3.1. Peptidyl (acyloxy)methyl ketones inhibit Rce1p
The enzymes evaluated in this study were isolated from
CaaX protease deficient yeast (MATa rce1Δ ste24Δ) engineered
to over-express the human, plant (Arabidopsis thaliana), or
native yeast Rce1p enzyme. Because the yeast CaaX proteases
localize to the endoplasmic reticulum (ER) compartment in
yeast, enriched ER membranes were used as the source of
enzyme activity for our experiments [4]. Using a previously
described fluorescence-based activity assay designed for human
Rce1p, we observed Rce1p dependent activity for all three
orthologs. Despite the common expression system and activity
assay, the specific activities for the isolated membranes were
quite distinct, with yeast Rce1p-containing membranes having
the highest value (3.48 nmol/min/mg of total membrane
protein), which was followed by plant and human Rce1p-
containing membranes (0.89 and 0.10 nmol/min/mg, respec-
tively). The activity observed was dependent on Rce1p since
membranes derived from yeast deficient in CaaX proteases had
inconsequential activity in this assay (0.0014 nmol/min/mg).
The reason for the varied specific activities is unknown but
could be attributable to differential enzymatic properties,
expression, localization, and/or substrate specificity. For
example, the specific activity of plant Rce1p is two-fold higher
at pH 6.0 than at pH 7.5 (the pH used in this study) while yeast
Rce1p has optimal activity at pH 7.5 and 35% less activity at pH
6.0.Using the fluorescence assay, we evaluated the inhibitor
profile of the three Rce1p orthologs. To facilitate cross-species
comparisons, the observed activities for each ortholog were
normalized to an appropriate mock treated control. Our analysis
revealed that the orthologs were all inhibited by TPCK and, to a
lesser extent, by TLCK (Fig. 2). Variations in sensitivity were
observed. For example, yeast Rce1p appeared least sensitive to
chloromethyl ketones by comparison to the other enzymes,
while human Rce1p had an increased sensitivity to TLCK by
comparison. When AOMKs were evaluated, we observed that
FKBK(CH3)3 inhibited all three Rce1p orthologs. Variations in
sensitivity to FKBK(CH3)3 were also observed. For example,
the human enzyme was relatively more sensitive than either the
yeast or plant enzyme. The related compound FABK(CH3)3
inhibited the three Rce1p orthologs to amuch lesser degree, even
at concentrations as high at 1 mM (86%, 87% and 74% activity
for Sc, At and Hs Rce1p respectively). This suggests that the
dipeptidyl portion of this class of compound impacts inhibitor
specificity by some manner. Generally, the three Rce1p enzymes
were found to be sensitive to TPCK and FKBK(CH3)3 and
relatively less sensitive to TLCK and FABK(CH3)3.
Because of the observed inhibition of Rce1p by FKBK
(CH3)3, we evaluated additional AOMKs using the Ras-based
fluorescence assay. The dipeptidyl AOMK FRBK(CH3)2 and
tripeptidyl AOMK YFRBK(CH3)2 are similar to FKBK(CH3)3
in that they have a charged amino acid in the last position of the
peptidyl portion of the compound (Fig. 1); they mainly differ in
having distinct peptidyl moieties and two rather than three
methyl substitutions on the benzoyl group. FRBK(CH3)2
inhibited Rce1p and was the most potent Rce1p inhibitor of
the AOMKs evaluated, whereas YFRBK(CH3)2 was the least
Table 2
Effect of chloromethyl ketones and peptidyl (acyloxy)methyl ketones on the in
vitro activity of yeast Rce1p and Ste24p
Compound % Activity remaining a
Rce1p Ste24p
FKBK(CH3)3 51.3±6.0 29.4±1.0
FABK(CH3)3 95.3±2.5 95.1±2.4
FRBK(CH3)2 41.0±4.4 58.6±0.3
FGBK(CH3)2 99.0±3.2 112.7±2.1
YFRBK(CH3)2 80.2±0.9 96.4±4.6
YFGBK(CH3)2 97.7±1.6 99.4±2.7
TPCK 77.4±1.3 92.3±3.4
TLCK 101.0±0.0 94.7±0.5
a Values are averages (n≥3 replicates) of percent activity remaining from
studies using 100 μM of the indicated compound relative to a DMSO-treated
control. Fig. 3. The sensitivity of yeast Rce1p to TPCK is substrate-specific. (A) The
inhibitory effect of various compounds on the activity of yeast Rce1p was
evaluated using an assay that monitors in vitro formation of the bioactive a-
factor mating pheromone. The reaction conditions were similar to those
described for Fig. 2, except that the compounds were used at 400 μM to pretreat
membranes and the initial proteolysis step of the reaction was followed by an in
vitromethylation step. A portion of the final sample and two-fold serial dilutions
were spotted onto a lawn of MATα sst2-1 cells that had been spread as a thin
lawn on a YEPD plate. This MATα background is supersensitive to the a-factor
mating pheromone and undergoes a strong growth arrest in its presence, as
indicated by a zone of no growth (spot) in the lawn after incubation of the plate
at 30 °C for 24 h. Each experiment was performed multiple times, and one
representative replicate is shown. (B) Graphical representation of data from trials
using the a-factor assay (top) or the fluorescence assay (bottom) with the values
at the top of each bar representing the average amount of activity observed. The
sample order in the two panels is identical.
Table 3
The effect of salt and urea washes on the in vitro activity of inhibitor-treated
yeast Rce1p and Ste24p
Wash a % Activity remaining
Rce1p Ste24p
DMSOb FKBK(CH3)3 DMSO FKBK(CH3)3
0 mM NaCl 100.0±0.5 27.3±1.0 100.0±0.7 30.3±3.5
125 mM NaCl 92.3±0.9 28.9±1.1 97.4±8.7 35.7±2.2
1500 mM NaCl 99.0±2.5 31.6±0.2 113.4±1.3 30.3±1.5
0 mM urea 100.0±0.6 37.9±0.4 100.0±5.5 20.4±10.7
62.5 mM urea 94.9±0.4 37.1±6.0 100.6±2.4 20.0±1.7
125 mM urea 92.6±2.1 39.3±0.6 96.2±3.5 19.4±0.5
a Membranes were pretreated with DMSO or 250 μM of FKBK(CH3)3 for
10 min at 30 °C before being washed.
b Values are averages (n≥2 replicates) of percent activity remaining after
treatment under the indicated condition. Values for DMSO-treated samples are
relative to the 0 mM wash condition. Values for FKBK(CH3)3-treated samples
are relative to the DMSO-treated sample washed under the same conditions.
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tripeptidyl YFGBK(CH3)2 are similar to FABK(CH3)3 in that
they have a small uncharged amino acid in the last position of
the peptidyl portion. None of these compounds inhibited Rce1p
activity. Our results suggest that a positively charged amino acid
in the last position of the dipeptidyl moiety of the AOMK is
required for the ability of this compound class to inhibit Rce1p.
3.2. The inhibition of yeast Rce1p by TPCK is
substrate-specific
To independently confirm the inhibitory effects of TPCK
and certain AOMKs, we evaluated these compounds using a
coupled CaaX proteolysis-methylation assay that generates the
bioactive a-factor mating pheromone [16]. This assay utilizes a
distinct substrate and readout that essentially eliminates any
interference arising from unanticipated autofluorescing or
quenching properties associated with compounds being
evaluated. Using the coupled assay, we surprisingly observed
that TPCK did not significantly inhibit a-factor production
(Fig. 3). An aliquot of the same TPCK-treated sample
demonstrated reduced Rce1p activity when evaluated using
the fluorescence assay (Fig. 3B, lower panel). Except for the
nature of the substrate, the reaction conditions for the
proteolytic step in both assays were identical (i.e., the same
buffer and concentrations of substrate and membrane). The
activity observed in the presence of TPCK in the a-factor
assay cannot be attributed to an unaccounted a-factor-specific
proteolytic activity because membranes lacking Rce1p and
Ste24p have insignificant activity in this assay [16]. Unlike
TPCK, FKBK(CH3)3 inhibited regardless of the assay used.
Consistent with our previous observations, neither TLCK nor
FABK(CH3)3 inhibited Rce1p to any significant extent when
evaluated using the a-factor assay.
3.3. Inhibition of Rce1p by FKBK(CH3)3 is not readily
reversible
As a first step toward investigating the nature of interaction
between AOMKs and Rce1p, we evaluated whether FKBK
(CH3)3-mediated inhibition was readily reversible by washinginhibitor-treated membranes with buffers containing salt (0–
1.5 M NaCl) or urea (0–0.125 M). The washes themselves did
not significantly affect the activity of untreated Rce1p by
comparison to an unwashed sample (data not shown). Using this
approach, we observed that FKBK(CH3)3-treated Rce1p could
not be reactivated by any of the wash conditions employed
(Table 3).
To further resolve the inhibitory mechanism of FKBK(CH3)3,
we examined the kinetics of enzyme inhibition. This analysis
revealed that FKBK(CH3)3 reduced the Vmax of Rce1p in a dose-
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concentration also reduced the Vmax of Rce1p, but to a lesser
extent. The observed Km values were essentially unchanged
relative to the untreated control. Linear transformations of the
kinetic data (e.g., Lineweaver–Burke analysis) revealed that
inhibition by FKBK(CH3)3 could be attributable to either aFig. 4. Kinetic analysis of FKBK(CH3)3 and TPCKmediated inhibition of Rce1p.
(A) FKBK(CH3)3 and TPCK both reduce the Vmax of Rce1p. Initial reaction rates
were determined after pretreatment with DMSO, 100 μM FKBK(CH3)3 or
100 μMTPCK using the fluorescence-based assay described in Fig. 2. Data points
were plotted and a best-fit curve determined by non-linear regression analysis
using Prism 4.0. (B) Summary of kinetic parameters observed after pretreatment
with inhibitors. Km and Vmax were determined by non-linear regression analysis.
(C) FKBK(CH3)3 is a fast-acting inhibitor of Rce1p. FKBK(CH3)3 and TPCK
were each used at 250 μM to pretreat Rce1p for the indicated times. Initial reaction
rates were determined at various time points (Et) and used to calculate enzyme
activity relative to the reaction rate for a DMSO-treated control at t=0 min (E0),
the time at which inhibitor and substrate were added simultaneously to the
enzyme. The natural log of the resultant Et/E0 values were plotted vs. time and a
best-fit line determined for each dataset. (D) FKBK(CH3)3 partitions with yeast
membranes. Samples containing buffer alone (buffer) or yeast membranes devoid
of CaaX protease activity (membranes) were incubated with DMSO or 100 μM
FKBK(CH3)3 for 10 min at 30 °C. The samples were centrifuged to clear
membrane material and the clarified supernatants were used to resuspend Rce1p-
containing membrane pellets that were prepared in parallel. The inhibitor activity
associated with each preconditioned sample was determined using the assay
described in Fig. 2. Values reported for FKBK(CH3)3 are relative to the DMSO
control for each condition.
Fig. 5. Quencher position impacts the specificity of Rce1p and Ste24p. The
cleavage of quenched fluorogenic peptides derived from K-Ras4b was evaluated
using yeast membrane extracts containing either yeast Rce1p or Ste24p and the
assay described in Fig. 2. The substrates vary in the position of the quenching
group, which is at either the a1 (CQLIM), a2 (CVQLM), or X position (CVIQL)
of the CaaX motif. Otherwise, the samples are identical to the substrate
described in Fig. 2. Incorporation of the quenching group at the a2 or X position
converts this substrate into a Ste24p reporter. The closed and open bars represent
the activities of Rce1p and Ste24p, respectively.reversible noncompetitive or irreversible mechanism. By point
of comparison, TPCK is reportedly an irreversible active-site
inhibitor of Rce1p [23]. One characteristic of this type of
inhibitor is that the extent of inhibition depends on time of
exposure. We found that FKBK(CH3)3 did not inhibit Rce1p in
a time-dependent manner (Fig. 4C) [23]. We should also note a
complicating issue regarding our analysis of kinetic parameters.
During the course of our investigations, we determined that
FKBK(CH3)3 partitions onto yeast membranes in a non-
selective manner (Fig. 4D). This observation suggests that the
amount of free inhibitor in solution is actually less than
predicted in our assays. This property would necessarily lead to
an overestimation of IC50 and could alter the kinetic parameters
observed in the presence of this compound.
3.4. Ste24p can be inhibited by AOMKs
In order to further understand the specificity of chloromethyl
ketones and AOMKs, we sought to determine the inhibitorFig. 6. Ste24p orthologs have comparable inhibitor profiles as measured using a
fluorescence assay. The inhibitory effect of the indicated compounds on the
activity of S. cerevisiae (Sc), A. thaliana (At), and human (Hs) Ste24p (A–C,
respectively) was evaluated as described in Fig. 2, except that a different
substrate (CVIQL) was used. All compounds were used at 250 μM to pretreat the
yeast-derived membranes used as the source of enzymatic activity. The DMSO-
treated sample was defined as having 100% activity for each membrane set to
facilitate cross-species comparative analyses.
Fig. 7. The sensitivity of Ste24p to select inhibitors is not substrate-specific. (A)
The inhibitory effect of various compounds on the activity of yeast Ste24p was
evaluated using the a-factor assay and conditions described in Fig. 3. (B)
Graphical representation of the data from all the trials (n>3) with the values at
the top of each bar representing the average amount of activity observed.
Fig. 8. The Ste14p isoprenylcysteine carboxyl methyltransferase is inhibited
by FKBK(CH3)3. The a-factor assay was used to test for inhibition of the
Ste14p ICMT. (A) FKBK(CH3)3 was added immediately prior to the Rce1p
mediated proteolysis step (Step 1) or the Ste14p mediated carboxyl
methylation step (Step 2) but otherwise using the conditions described in
Fig. 3. A representative replicate data set (top panel) and a graph
summarizing the results of the experiment (bottom panel) are shown. (B)
FKBK(CH3)3 was added to Step 1 or Step 2 as described in A, but in the
presence of a limiting amount of Ste14p.
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we developed a fluorescence-based assay to monitor Ste24p
activity. Initially, we evaluated the Rce1p substrate (CQLIM) for
its ability to be cleaved by yeast Ste24p and determined that it
was a poor substrate (Fig. 5); similar results were obtained for
plant and human Ste24p (Porter and Schmidt, unpublished
observation). We next evaluated isoprenylated substrates that
differed only in the placement of the quenching group. This
analysis revealed that yeast Ste24p had a marked preference for
the quencher at either the a2 (CVQLM) or X position (CVIQL)
of the CaaX motif relative to the a1 position (CQLIM), while
yeast Rce1p had a marked preference for the quencher at the a1
position. Using the CVIQL fluorogenic substrate, we deter-
mined the specific activities of several Ste24p orthologs. These
values varied as had been observed for the Rce1p orthologs.
Yeast Ste24p had the highest specific activity, followed by the
human and plant enzymes (9.41 nmol/min/mg, 1.43 nmol/min/
mg, and 1.01 nmol/min/mg of total membrane protein,
respectively). To our knowledge, this is the first assay described
that is amenable for kinetic analyses of Ste24p activity.
Accordingly, we have determined that yeast Ste24p has a Km
of 10.9 μM using the CVIQL fluorogenic substrate and
nonlinear regression methods.
Using the fluorescence-based assay, we evaluated the
inhibitor profile of three Ste24p orthologs (Sc Ste24p, At
Ste24p, and Hs Ste24p). FKBK(CH3)3 consistently inhibited
these enzymes (Fig. 6). FABK(CH3)3 was a weak inhibitor at
best, with human Ste24p appearing to be the most sensitive of
the group. Neither TPCK nor TLCK had significant inhibitory
activity. Yeast Ste24p was also determined to be inhibited by
FRBK(CH3)2, but not by FGBK(CH3)2 or tripeptidyl AOMKs
(Table 2). To investigate whether the observed inhibition profile
of Ste24p was substrate-specific, we evaluated the effects of
these compounds using the a-factor based assay. Paralleling our
results with Rce1p, we observed that TPCK did not inhibit yeast
Ste24p, whereas FKBK(CH3)3 remained a potent inhibitor by
comparison (Fig. 7). Like Rce1p, we also observed that theinhibition of Ste24p by FKBK(CH3)3 was not readily reversible
(Table 3).
3.5. FKBK(CH3)3 inhibits the Ste14p ICMT
The ability of FKBK(CH3)3 to inhibit both Rce1p and
Ste24p prompted us to examine whether the isoprenylcysteine
carboxyl methyltransferase (ICMT) was a target of this
compound. The integral membrane protein Ste14p is the yeast
ICMT [20]. To investigate this issue, we took advantage of the
fact that a-factor production relies on a coupled assay having
distinct proteolytic and methylation steps (Steps 1 and 2,
respectively). Thus, the inhibition of Ste14p can be evaluated by
simply adding the agent after proteolysis has been completed
and the protease heat-inactivated (Step 1). Under standard
reaction conditions where Ste14p activity was added in excess,
FKBK(CH3)3 had only a modest inhibitory effect on a-factor
production when added during Step 2 (Fig. 8A). The inhibition
was less than that observed when added during Step 1,
suggesting that FKBK(CH3)3 does indeed inhibit the CaaX
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assay with this compound is due to synergistic inhibition of the
CaaX protease and ICMT. The inhibitory effect of FKBK
(CH3)3 was exaggerated when limiting amounts of Ste14p were
present in the reaction (Fig. 8B), demonstrating that the ICMT is
indeed inhibited by FKBK(CH3)3.
4. Discussion
This study reports several new findings. First, we document
using a single expression system that Rce1p orthologs have a
similar inhibitor profile to certain agents (Fig. 2). This
observation, when combined with the observation that Rce1p
orthologs have conserved substrate specificity, strengthens the
assertion that enzymatic studies of yeast Rce1p and other non-
human orthologs will ultimately lead to a better understanding
of the human enzyme, which is of biomedical importance [28].
Second, our study demonstrates that TPCK is an unreliable
diagnostic inhibitor of Rce1p (Table 2 and Fig. 3). This finding
suggests the use of caution when interpreting previous studies
where TPCK was used in efforts to define the mechanistic class
of the enzyme [24,27]. Lastly, we describe peptidyl AOMKs as
novel agents that inhibit both Rce1p and Ste24p (Table 2), and
in doing so we developed a new in vitro assay for monitoring
Ste24p activity (Figs. 5 and 6). The AOMKs themselves
represent new and potentially useful tools for investigating
Rce1p and Ste24p enzymology that can perhaps serve as the
basis for developing more potent inhibitors of these enzymes.
This latter point is supported by the observation that varying the
peptidyl moiety of AOMKs can yield an improved Rce1p
inhibitor (i.e. FRBK(CH3)2). While no single AOMK evaluated
in this study was absolutely specific for either Rce1p or Ste24p,
our observation that Rce1p and Ste24p display differential
sensitivity to certain AOMKs suggests that Rce1p or Ste24p
specific inhibitors might be extractable from this class of
compounds (Table 2).
Our observation that substrate context impacts the effective-
ness of Rce1p inhibitors could explain the inconsistent effect of
serine protease inhibitors and alkylating agents on Rce1p
activity [24,27,30,31]. We thus suggest that evaluating
inhibitors of Rce1p in the context of multiple substrates is the
best way to fully ascertain the inhibitory properties of a
particular compound for this multi-substrate enzyme. Rce1p
mutants should be similarly evaluated since we have observed
that the activities of certain Rce1p mutants are substrate
dependent [28]. We suspect that substrate context may also
explain why yeast Rce1p C251A is reported to be both active
and inactive [24,28]. While we do not observe activity defects
for Rce1p C251A when using any of our in vitro or in vivo
assays, it remains a formal possibility that the initial report on
this particular mutant utilized an enzyme/substrate combination
that uncovers sensitivities that our combinations did not. The
fact that most studies of Rce1p have been performed using a
single enzyme/substrate combination certainly raises important
concerns regarding the interpretation of reported data. We fully
expect to continue evaluating Rce1p in the context of multiple
substrates because of this issue.Despite AOMKs being described as cysteine protease-
specific inhibitors that are proposed to mediate their effects
through covalent modification of an active site cysteine
residue, it is unlikely that this mechanism applies in the
context of Rce1p. First, we have observed that yeast Rce1p
C251A is fully functional [28]; C251 is the only cysteine
found among Rce1p orthologs that is invariably conserved.
Moreover, we have observed that FKBK(CH3)3 inhibits Rce1p
C251A to the same extent as the wildtype enzyme. Second, the
fact that Ste24p and Ste14p, two enzymes reportedly lacking
active site cysteine residues, are inhibited by FKBK(CH3)3
argues against a cysteine-directed modification. Lastly, muta-
tional and bioinformatic analyses do not support Rce1p being a
cysteine protease.
All together, our kinetic data suggest that FKBK(CH3)3 is a
tightly bound but otherwise reversible noncompetitive inhibitor
of Rce1p. We do not believe that FKBK(CH3)3 acts as an
irreversible inhibitor because of a lack of time dependent
behavior, but we cannot formally exclude that FKBK(CH3)3
acts faster than we can measure with our existing assays.
Another caveat that must be considered is the propensity of
FKBK(CH3)3 to partition with yeast membranes. This property
necessarily alters the amount of free inhibitor available for
interacting with Rce1p and could markedly alter our reported
IC50 values and kinetic parameters. Whether other reported
Rce1p inhibitors have the same property has not been
addressed, but should be considered given our observations.
Despite the above caveats, it is clear that FKBK(CH3)3 inhibits
three distinct enzymes involved in CaaX protein maturation.
Among several possible explanations for this observation, we
suggest that FKBK(CH3)3 might be an inhibitor that binds to a
common structural feature that is possessed by Rce1p, Ste24p,
and Ste14p. Alternatively, FKBK(CH3)3 may perturb some
aspect of membrane association or metal ion coordination, the
latter being proposed as a shared property of these enzymes
[16,22,37,47].
As for TPCK, our data are consistent with it being an
active-site irreversible inhibitor of yeast Rce1p, which is the
reported mechanism described for this agent in the context of
bovine Rce1p [23]. It is challenging to explain, however, the
apparent substrate-specific inhibitory properties of TPCK.
Among several possibilities, we suggest that the presence of
TPCK at the active site interferes with the binding of low-
affinity substrates (i.e. the highly charged K-Ras4b based
fluorescent peptide) more so than high affinity substrates (i.e.
the highly hydrophobic a-factor based peptide). It is also
plausible that TPCK might bind Rce1p in a way that induces
allosteric effects that alter substrate binding in a similar
manner. Of note, TPCK is not the only substrate-specific
inhibitor of Rce1p. In a recent screen aimed at identifying
small molecule in vitro inhibitors of Rce1p, over 80% of hits
found to inhibit cleavage of the fluorogenic K-Ras4b substrate
were determined to be ineffective at preventing Rce1p-
dependent a-factor production [48]. Clearly, determining the
structure of Rce1p in complex with TPCK, an inhibitory
AOMK, or any inhibitor is likely to resolve the mode of
inhibition for these agents, but this is a daunting task given that
861S.B. Porter et al. / Biochimica et Biophysica Acta 1773 (2007) 853–862Rce1p is an integral membrane protein possessing multiple
membrane spans.
This study has provided new insight into the complex
enzymology of Rce1p and new tools for future studies of the
CaaX proteases. For example, our observation that dipeptidyl
AOMKs can inhibit two presumably distinct proteases suggests
that the mechanisms and/or active sites of the CaaX proteases
Rce1p and Ste24p are more similar than previously perceived.
Our findings also suggest that AOMKs could be modified into
more potent and potentially specific inhibitors of either or both
of the CaaX proteases. Finally, this study highlights the
important need to evaluate enzyme inhibitors in the context of
multiple substrates.
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